144 related articles for article (PubMed ID: 26056491)
1. Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/desogestrel 150 μg (21/7 regimen).
Bitzer J; Banal-Silao MJ; Ahrendt HJ; Restrepo J; Hardtke M; Wissinger-Graefenhahn U; Trummer D
Int J Womens Health; 2015; 7():501-9. PubMed ID: 26056491
[TBL] [Abstract][Full Text] [Related]
2. Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.
Anttila L; Neunteufel W; Petraglia F; Marr J; Kunz M
Clin Drug Investig; 2011; 31(8):519-525. PubMed ID: 21721590
[TBL] [Abstract][Full Text] [Related]
3. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Gerlinger C; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.
Guang-Sheng F; Mei-Lu B; Li-Nan C; Xiao-Ming C; Zi-Rong H; Zi-Yan H; Xiao-Ping J; Jian L; Shu-Ying W; Cheng-Liang X; Zheng-Ai X; Tian-Fu Y
Clin Drug Investig; 2010; 30(6):387-96. PubMed ID: 20201608
[TBL] [Abstract][Full Text] [Related]
5. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
[TBL] [Abstract][Full Text] [Related]
6. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
Contraception; 2001 Sep; 64(3):201-7. PubMed ID: 11704101
[TBL] [Abstract][Full Text] [Related]
7. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg.
Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():17-25. PubMed ID: 14677621
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20mug and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20mug and desogestrel 150mug.
Gruber DM; Huber JC; Melis GB; Stagg C; Parke S; Marr J
Treat Endocrinol; 2006; 5(2):115-21. PubMed ID: 16542051
[TBL] [Abstract][Full Text] [Related]
9. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
Keam SJ; Wagstaff AJ
Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554
[TBL] [Abstract][Full Text] [Related]
10. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
[TBL] [Abstract][Full Text] [Related]
11. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel.
Foidart JM; Wuttke W; Bouw GM; Gerlinger C; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Jun; 5(2):124-34. PubMed ID: 10943575
[TBL] [Abstract][Full Text] [Related]
12. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
Machado RB; Pompei LM; Badalotti M; Ferriani R; Cruz AM; Nahas E; Maia H
Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):11-16. PubMed ID: 27684740
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
[TBL] [Abstract][Full Text] [Related]
14. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study.
Macìas G; Merki-Feld GS; Parke S; Mellinger U; Serrani M
J Obstet Gynaecol; 2013 Aug; 33(6):591-6. PubMed ID: 23919857
[TBL] [Abstract][Full Text] [Related]
15. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.
Seidman L; Kroll R; Howard B; Ricciotti N; Hsieh J; Weiss H
Contraception; 2015 Jun; 91(6):495-502. PubMed ID: 25746294
[TBL] [Abstract][Full Text] [Related]
16. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
17. Hormone withdrawal-associated symptoms: comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate.
Jensen JT; Parke S; Mellinger U; Serrani M; Mabey RG
Eur J Contracept Reprod Health Care; 2013 Aug; 18(4):274-83. PubMed ID: 23638631
[TBL] [Abstract][Full Text] [Related]
18. User satisfaction with the combined oral contraceptive drospirenone 3 mg/ethinylestradiol 20 microg (Yasminelle) in clinical practice: a multi-country, questionnaire-based study.
Short M
Clin Drug Investig; 2009; 29(3):153-9. PubMed ID: 19243208
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.
Timmer CJ; Mulders TM
Clin Pharmacokinet; 2000 Sep; 39(3):233-42. PubMed ID: 11020137
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study.
Momoeda M; Kondo M; Elliesen J; Yasuda M; Yamamoto S; Harada T
Int J Womens Health; 2017; 9():295-305. PubMed ID: 28496369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
